J&J says that it is discontinuing work on the neurotoxin program for PurTox, its long-acting successor to Botox, even though its Mentor subsidiary has wrapped three late-stage studies on the aesthetic therapy for smoothing out facial wrinkles.
After 19 years of fruitless drug development work capped by the failure of a Phase IIb study of its experimental asthma therapy, Cytos Biotechnology is ready to call it quits.
Merck may be late to the blockbuster party with its new hepatitis C drugs, but the pharma giant is moving fast with a top contender boasting high cure rates.
Merck KGaA has breathed some life back into its lung cancer vaccine, which many wrote off after it tanked in a Phase III trial in late 2012. After vowing to make a renewed effort to find some value in the jab last September, this week the company announced the start of a new Phase III study.
The latest news sliced only 3% off the biotech's share price.
Alkermes has crossed the finish line in a Phase III schizophrenia study of a long-acting version of Abilify, picking up the statistically significant results needed to back a new drug application later in the year.
Puma Biotechnology is boasting that its experimental cancer drug neratinib bested Herceptin in a head-to-head study of HER2-positive breast cancer when used ahead of surgery.
Agios Pharmaceuticals was the biotech canary in the coal mine when it went public last year. Not only did it survive its IPO, it thrived, helping lure dozens of other biotechs into the market with solid proof that investors would buy into a drug developer with no human data in the portfolio.
Global CRO Clinipace has agreed to manage clinical trials for Nexstim as the Finnish devicemaker works toward FDA approval for its neurostimulation therapy.
In the first detailed glimpse of palbociclib's impact on overall survival--a key feature to the future prospects of this flagship program--the therapy has failed to demonstrate a statistically significant improvement in extending patients' lives after an initial assessment.